| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 2, 2026Next | Q3 2026 | Before market open | 4.04 | 1.77 B |
Aug 28, 2026
Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.82% on an annualized basis producing an average annual return of 12.05%. Currently, Waters has a market capitalization of $41.46 billion. Buying
Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Aug 27, 2026
Top Wall Street analysts upgraded BWX Technologies, The Macerich Company, and Waters Corporation. Check out analyst ratings and price targets.
Piper Sandler analyst David Westenberg upgrades Waters (NYSE:WAT) from Neutral to Overweight and raises the price target from $400 to $480.
Aug 26, 2026
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.
Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10:15 AM Eastern Time.
Aug 13, 2026
Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The
Aug 11, 2026
Organic growth accelerated to 9% as acquired units and legacy markets recovered.
Aug 10, 2026
Citigroup analyst Joanne Wuensch maintains Waters (NYSE:WAT) with a Buy and raises the price target from $425 to $470.
Aug 9, 2026
Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve
Aug 8, 2026
Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...
Aug 7, 2026
2026-08-07. The following slide deck was published by Waters Corporation in conjunction with their 2026 Q2 earnings call.
Aug 6, 2026
Aug 5, 2026
WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.
TD Cowen analyst Dan Brennan upgrades Waters (NYSE:WAT) from Hold to Buy and raises the price target from $408 to $475.
RBC Capital analyst Dan Leonard maintains Waters (NYSE:WAT) with a Outperform and raises the price target from $435 to $475.
Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:WAT) with a Outperform and raises the price target from $410 to $420.
Wells Fargo analyst Evan Stampler maintains Waters (NYSE:WAT) with a Equal-Weight and raises the price target from $370 to $400.
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $425 to $460.
Aug 4, 2026
Moby summary of Waters Corporation's Q2 2026 earnings call
